Table 2.
Ref. | RCT | Pts (IFX vs control ) (n) | PO morbidity (IFX vs control ) | P value | PO infectious complications (IFX vs control) | P value |
Schluender et al[64] | N | 17 vs 134 | 36% vs 28% | > 0.05 | 18% vs 8% | > 0.05 |
Selvasekar et al[62] | N | 47 vs 254 | 62% vs 49% | 0.10 | 28% vs 10% | < 0.01 |
Mor et al[63] | N | 46 vs 46 | 34.8% vs 15.2% | 0.004 | 21.7% vs 2.2% | 0.011 |
Ferrante et al[65] | N | 22 vs 119 | 11.1% vs 28.6% | > 0.05 | 9% vs 24% | 0.161 |
Gainsbury et al[66] | N | 29 vs 52 | 44.8% vs 44.2% | 0.96 | 17.2% vs 26.9% | 0.32 |
Rizzo et al[67] | N | 16 vs 22 | 37.5% vs 22.7% | > 0.05 | 18.7% vs 18.2% | > 0.05 |
RCT: Randomized controlled trial; Pts: Patients; PO: Post-operative; IFX: Infliximab; Y: Yes.